Vertex Pharmaceuticals (VRTX) Cash from Operations Growth (3y) (2012 - 2026)
Vertex Pharmaceuticals (VRTX) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 33.08% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 34.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.64% |
| Dec 31, 2025 | -22.71% |
| Sep 30, 2025 | 9.12% |
| Jun 30, 2025 | -1.99% |
| Mar 31, 2025 | -5.04% |
| Dec 31, 2024 | -16.24% |
| Sep 30, 2024 | 13.89% |
| Jun 30, 2024 | -165.88% |
| Mar 31, 2024 | 12.36% |
| Dec 31, 2023 | -21.85% |
| Sep 30, 2023 | 11.80% |
| Jun 30, 2023 | 2.99% |
| Mar 31, 2023 | 3.33% |
| Dec 31, 2022 | 34.22% |
| Sep 30, 2022 | 41.85% |
| Jun 30, 2022 | 34.95% |
| Mar 31, 2022 | 43.32% |
| Dec 31, 2021 | 46.79% |
| Sep 30, 2021 | 34.47% |
| Jun 30, 2021 | -37.87% |